339 related articles for article (PubMed ID: 25724760)
1. Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?
Li ML; Hu XQ; Li F; Gao WJ
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jul; 60():66-76. PubMed ID: 25724760
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action?
Ghose S; Gleason KA; Potts BW; Lewis-Amezcua K; Tamminga CA
Am J Psychiatry; 2009 Jul; 166(7):812-20. PubMed ID: 19487395
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists.
Nakazato A; Kumagai T; Sakagami K; Yoshikawa R; Suzuki Y; Chaki S; Ito H; Taguchi T; Nakanishi S; Okuyama S
J Med Chem; 2000 Dec; 43(25):4893-909. PubMed ID: 11123999
[TBL] [Abstract][Full Text] [Related]
4. Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia.
Fraley ME
Expert Opin Ther Pat; 2009 Sep; 19(9):1259-75. PubMed ID: 19552508
[TBL] [Abstract][Full Text] [Related]
5. Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia.
Chaki S
Eur J Pharmacol; 2010 Aug; 639(1-3):59-66. PubMed ID: 20371240
[TBL] [Abstract][Full Text] [Related]
6. mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.
Engel M; Snikeris P; Matosin N; Newell KA; Huang XF; Frank E
Psychopharmacology (Berl); 2016 Apr; 233(8):1349-59. PubMed ID: 26861891
[TBL] [Abstract][Full Text] [Related]
7. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice.
Galici R; Jones CK; Hemstapat K; Nong Y; Echemendia NG; Williams LC; de Paulis T; Conn PJ
J Pharmacol Exp Ther; 2006 Jul; 318(1):173-85. PubMed ID: 16608916
[TBL] [Abstract][Full Text] [Related]
8. Juvenile treatment with mGluR2/3 agonist prevents schizophrenia-like phenotypes in adult by acting through GSK3β.
Xing B; Han G; Wang MJ; Snyder MA; Gao WJ
Neuropharmacology; 2018 Jul; 137():359-371. PubMed ID: 29793154
[TBL] [Abstract][Full Text] [Related]
9. Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia.
Kanuma K; Aoki T; Shimazaki Y
Recent Pat CNS Drug Discov; 2010 Jan; 5(1):23-34. PubMed ID: 19832691
[TBL] [Abstract][Full Text] [Related]
10. Investigating the role of mGluR2 versus mGluR3 in antipsychotic-like effects, sleep-wake architecture and network oscillatory activity using novel Han Wistar rats lacking mGluR2 expression.
Wood CM; Wafford KA; McCarthy AP; Hewes N; Shanks E; Lodge D; Robinson ESJ
Neuropharmacology; 2018 Sep; 140():246-259. PubMed ID: 30005976
[TBL] [Abstract][Full Text] [Related]
11. Density of metabotropic glutamate receptors 2 and 3 (mGluR2/3) in the dorsolateral prefrontal cortex does not differ with schizophrenia diagnosis but decreases with age.
Frank E; Newell KA; Huang XF
Schizophr Res; 2011 May; 128(1-3):56-60. PubMed ID: 21334855
[TBL] [Abstract][Full Text] [Related]
12. The crosstalk between 5-HT
Saha S; González-Maeso J
Neuropharmacology; 2023 Jun; 230():109489. PubMed ID: 36889432
[TBL] [Abstract][Full Text] [Related]
13. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.
Fell MJ; McKinzie DL; Monn JA; Svensson KA
Neuropharmacology; 2012 Mar; 62(3):1473-83. PubMed ID: 21704048
[TBL] [Abstract][Full Text] [Related]
14. Positive and negative modulation of circadian activity rhythms by mGluR5 and mGluR2/3 metabotropic glutamate receptors.
Gannon RL; Millan MJ
Neuropharmacology; 2011; 60(2-3):209-15. PubMed ID: 20831878
[TBL] [Abstract][Full Text] [Related]
15. Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia.
Kinon BJ; Gómez JC
Neuropharmacology; 2013 Mar; 66():82-6. PubMed ID: 22722029
[TBL] [Abstract][Full Text] [Related]
16. mGluR3 and not mGluR2 receptors mediate the efficacy of NAAG peptidase inhibitor in validated model of schizophrenia.
Olszewski RT; Bzdega T; Neale JH
Schizophr Res; 2012 Apr; 136(1-3):160-1. PubMed ID: 22300789
[No Abstract] [Full Text] [Related]
17. Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: II. Glutamate (Ant)agonists.
Carfagno ML; Hoskins LA; Pinto ME; Yeh JC; Raffa RB
Ann Pharmacother; 2000 Jun; 34(6):788-97. PubMed ID: 10860140
[TBL] [Abstract][Full Text] [Related]
18. LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia.
Mezler M; Geneste H; Gault L; Marek GJ
Curr Opin Investig Drugs; 2010 Jul; 11(7):833-45. PubMed ID: 20571979
[TBL] [Abstract][Full Text] [Related]
19. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia.
Chavez-Noriega LE; Schaffhauser H; Campbell UC
Curr Drug Targets CNS Neurol Disord; 2002 Jun; 1(3):261-81. PubMed ID: 12769619
[TBL] [Abstract][Full Text] [Related]
20. Metabotropic glutamate receptors as targets for novel antipsychotic treatments.
Gray LJ; Hannan AJ; Zhang X
Curr Pharm Biotechnol; 2012 Jun; 13(8):1522-34. PubMed ID: 22283756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
